Pharma Focus Asia
KP - Choose our fully recyclable blister films

SK Biopharmaceuticals Enters MENA through Strategic Partnership with Hikma

Saturday, August 19, 2023

SK Biopharmaceuticals has entered into strategic and licencing agreements with Hikma to expand its presence into the Middle East and North Africa (MENA) region.

The agreement between SK Biopharmaceuticals and Hikma provides Hikma with exclusive rights to commercialise cenobamate, a drug developed by SK Biopharmaceuticals, in the Middle East and North Africa (MENA) region.

This exclusive commercialisation right extends to some of the most significant countries in the region, including Saudi Arabia, Egypt, and Algeria. This collaboration follows SK Biopharmaceuticals' efforts to expand its reach globally, as they have already ventured into North America, Northeast Asia, and Latin America to enhance patient access to cenobamate on a worldwide scale.

The partnership with Hikma is another step towards achieving these goals, and it signifies SK Biopharmaceuticals' dedication to expanding their market presence and making their innovative medications available to patients in regions where there is a significant medical need.

Latest Issue
Get instant
access to our latest e-book
THERMOFISHER SEACertara - Is your drug program on trackMasterControl - Manufacturing demoMasterControl - QMS demoThermo Fisher Scientific - Rapid Mycoplasma TestingThermoFisher Scientific - Save costs on your downstream process todayThermo Fisher Scientific - PeptonesMerck - Mobius® products5th Annual Pharma Manufacturing and Automation Convention 2023DUPHAT 202410TH ANNUAL GCC PHARMACY CONGRESS 202314th Annual Emirates Cardiac Society Conference 2023The International Hand & Wrist Congress 2023LabAsia 2023Pharma & Patient USA 2023Pharma Customer Engagement Europe 2023CHEMICAL INDONESIA 2024INALAB 2024